J&J. Issues press release about "final rejection" in re-exam of Remicade patent

The press release states:

--

NEW BRUNSWICK, N.J., Feb. 12, 2015 /PRNewswire/ -- Johnson & JohnsonJNJ, +0.31% today announced receipt of a further action from the Patent and Trademark Office regarding the re-examination of U.S. Patent No. 6,284,471 ('471) relating to REMICADE® issuing a final rejection of the patent.

We have sixty days to respond to this action and will do so. Currently the '471 patent expires in September 2018. We believe the '471 patent is valid and, if necessary, will pursue all available appeals.

--


Note link:
http://www.streetinsider.com/Corporate+News/Johnson+%26+Johnson+%28JNJ%29+Confirms+USPTO+Final+Rejection+of+REMICADE+Patent/10262569.html

See also

Hospira's Remicade copycat up for FDA review as US biosimilars March on

By Dan Stanton+, 13-Feb-2015

The US FDA has set a date to review its first monoclonal antibody (mAb) biosimilar: a version of J&J’s Remicade marketed by Pfizer takeover target Hospira.

http://www.biopharma-reporter.com/Markets-Regulations/Hospira-s-Remicade-copycat-up-for-review-as-US-biosimilars-March-on